Ingredion Incorporated reports Q1 2026 earnings on May 5 with short interest climbing sharply — the most notable shift on this name in weeks.
Short interest has rebounded hard after a significant unwind. It peaked at roughly 8% of free float on April 1, then collapsed to around 3% by mid-April. This week it reversed again, jumping 33% over seven days to land back at 4.0% of float. That reversal is the clearest positioning signal heading into Tuesday's number. The move happened quickly — short shares went from 1.9 million on April 22 to 2.5 million by April 24, a build of roughly 560,000 shares in two sessions. The sharp oscillations over the past month suggest traders have been actively adjusting views around both the tariff environment and the upcoming print.
The lending market offers little resistance to those rebuilding shorts. Cost to borrow is just 0.51%, up about 13% over the month but still historically low. Availability is not a constraint — with utilization at only 9.4%, well off the 21.2% peak hit on April 1, there is ample room in the lending pool. Options positioning leans the other way, with the put/call ratio at 0.36, slightly below its 20-day average of 0.40. That mild tilt toward calls suggests options traders are not hedging aggressively ahead of the print — a mild contrast to the short-side rebuilding underway in the stock loan market.
The Street is cautiously constructive but trimming its ambitions. Oppenheimer maintained its Outperform rating on April 22 while cutting its target from $130 to $126 — calling for healthy results but acknowledging near-term headwinds. UBS sits at Neutral with a $122 target, down from $124 following a reduction in early April. Benchmark initiated coverage in March with a Buy and a $130 target, adding a lone bullish voice. The consensus mean target of $126.57 implies roughly 13% upside from the current $111.71 — not a demanding bar, but the direction of recent revisions is downward. A preview piece flagged Q1 earnings expectations pointing to a year-over-year decline in results, consistent with the cautious target trimming from the two most active analysts on the name. Valuation is undemanding at 9.8x trailing earnings and 6.3x EV/EBITDA, with both multiples broadly flat over the past month.
The most recent full-year result gave bulls something to work with — full-year 2025 diluted EPS came in at $11.18, up from $9.71 in 2024, even as revenues slipped from $7.43 billion to $7.22 billion. The Q4 2025 print on February 3 delivered a 2.3% one-day gain and a modest +1.2% five-day move. That reaction history is benign — neither a blow-up nor a big rally — suggesting the stock has tended to absorb earnings without fireworks in recent quarters. Still, the sharp SI rebuild this week implies some market participants see May 5 as a more meaningful inflection point than the February print suggested.
Institutional ownership is broadly passive and stable. Vanguard and BlackRock together hold over 21% of shares. First Trust added a notable 971,000 shares in the most recent filing period, the largest active addition among top holders. Insider activity has been entirely selling since at least February, including a $1.16 million disposal by the Chairman and CEO on February 18 — though the size relative to the company's float is small and the trades carry low significance scores. Among peers, MDLZ gained 8.9% on the week while PPC fell 5.4%, pointing to divergent sector sentiment ahead of a busy food-ingredients earnings calendar.
The gap between where short interest sat two weeks ago and where it is today makes the May 5 print the natural focal point — and the degree to which Q1 results close or widen the distance to analyst targets will determine whether the rebuilding shorts or the passive longs prove better positioned.
See the live data behind this article on ORTEX.
Open INGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
